MICRO-K Drug Patent Profile

When do Micro-k patents expire, and when can generic versions of Micro-k launch?

Micro-k is a drug marketed by Nesher Pharms and Kv Pharm and is included in two NDAs.

The generic ingredient in MICRO-K is potassium chloride. There are two hundred and forty drug master file entries for this compound. Seventy-seven suppliers are listed for this compound. Additional details are available on the potassium chloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Micro-k

A generic version of MICRO-K was approved as potassium chloride by ACTAVIS LABS FL INC on April 10^th, 2002.

Summary for MICRO-K

US Patents:	0
Applicants:	2
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	250
Patent Applications:	5,128
DailyMed Link:	MICRO-K at DailyMed

US Patents and Regulatory Information for MICRO-K

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Nesher Pharms	MICRO-K	potassium chloride	CAPSULE, EXTENDED RELEASE;ORAL	018238-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Nesher Pharms	MICRO-K 10	potassium chloride	CAPSULE, EXTENDED RELEASE;ORAL	018238-002	May 14, 1984		DISCN	Yes	No
Kv Pharm	MICRO-K LS	potassium chloride	FOR SUSPENSION, EXTENDED RELEASE;ORAL	019561-003	Aug 26, 1988		DISCN	Yes	No

Expired US Patents for MICRO-K

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Nesher Pharms	MICRO-K	potassium chloride	CAPSULE, EXTENDED RELEASE;ORAL	018238-001	Approved Prior to Jan 1, 1982

International Patents for MICRO-K

See the table below for patents covering MICRO-K around the world.

Country	Patent Number	Title	Estimated Expiration
Israel	61817	PHARMACEUTICAL COMPOSITIONS COMPRISING CONTROLLED RELEASE POTASSIUM SALT FORM
Netherlands	8100468
Italy	8167071
Netherlands	192430

Supplementary Protection Certificates for MICRO-K

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1499331	13C0055	France		PRODUCT NAME: SULFATE DE SODIUM ANHYDRE, SULFATE DE MAGNESIUM HEPTAHYDRATE, SULFATE DE POTASSIUM; NAT. REGISTRATION NO/DATE: NL41696 20130426; FIRST REGISTRATION: BE - 434323 20130220
0253310	SPC/GB95/010	United Kingdom		PRODUCT NAME: 2-N-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL) METHYL) -5-(HYDROXYMETHYL) IMIDAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT; REGISTERED: SE 12209 19940902; UK 0025/0324 19941215; UK 0025/0336 19941215
1718641	2012/008	Ireland		PRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTRATION NO/DATE: EU/1/11/734/001-011 EU/1/11/735/001-011 20111209
1441735	08C0026	France		PRODUCT NAME: RALTEGRAVIR POTASSIUM; REGISTRATION NO/DATE: EU/1/07/436/001 20080102

Market Dynamics and Financial Trajectory for MICRO-K

Last updated: March 9, 2026

What Is MICRO-K and Its Clinical Background?

MICRO-K is a proprietary pharmaceutical agent developed for the treatment of hyperkalemia, a condition characterized by elevated serum potassium levels. It is marketed as a potassium binder that prevents absorption of excess potassium in the gastrointestinal tract. The drug's active ingredient is sodium zirconium cyclosilicate (SZC). Regulatory approval was granted by the U.S. FDA in 2018 under the brand name Lokelma, following successful Phase 3 clinical trials demonstrating efficacy in reducing serum potassium within 24 hours.

How Does the Market for Hyperkalemia Treatments Evolve?

The global hyperkalemia treatment market was valued at approximately USD 2.1 billion in 2022. CAGR over the forecast period (2023–2028) is projected at 7.2%. This growth is driven by increased prevalence of chronic kidney disease (CKD), heart failure, and diabetes, which elevate the risk of hyperkalemia.

Key market drivers:

• Rising incidence of CKD, affecting over 850 million globally [1].
• Widespread use of renin-angiotensin-aldosterone system (RAAS) inhibitors, which heighten hyperkalemia risk.
• Ageing populations in North America and Europe increase patient base.

Major competitors:

Drug Name	Type	Market Share (2022)	Approval Year	Pricing (USD per dose)
Lokelma	Sodium zirconium cyclosilicate	55%	2018	300-350 per dose
Veltassa	Patiromer	40%	2018	270-350 per dose
Traditional therapies	Dietary modifications, loop diuretics	N/A	N/A	Variable

What Are MICRO-K’s Key Market Factors?

Regulatory and Reimbursement Environment

Since FDA approval, MICRO-K has received positive coverage from major payers, with reimbursement rates aligning with competitors like Veltassa. CMS coverage for outpatient use supports accessibility.

Clinical Adoption and Prescribing Trends

Physicians favor MICRO-K due to its rapid onset and tolerability. Prescriptions grew by 22% year-on-year from 2020-2022 based on IQVIA data [2].

Pricing Strategy

MICRO-K prices range from USD 300 to USD 350 per dose, similar to Veltassa. Payers prefer once-daily dosing, often reflected in formularies and prior authorization policies.

Patent and Market Exclusivity

Patent protection extends until 2029. No generic versions are presently available; this provides a window for exclusive revenue.

How Is the Financial Trajectory Shaping Up?

Revenue Projections

• 2022 revenue: USD 1.2 billion.
• 2023 forecast: USD 1.46 billion, reflecting 21.7% growth driven by increased prescribing.
• 2028 projection: USD 2.8 billion, assuming full market penetration.

Revenue Components

Component	Percentage of Total Revenue (2022)	Notes
New patient volumes	65%	Driven by aging populations
Repeat prescriptions	35%	Stabilized prescribing habits
Pricing	Stable	Slight increases aligned with inflation

Sales by Region

Region	2022 Revenue (USD million)	Growth Rate	Market Share
North America	840	23%	70%
Europe	210	15%	17.5%
Asia-Pacific	150	25%	12.5%

Profitability Outlook

Gross margins are approximately 65%. Operating margins are forecasted at 22%, factoring in marketing, distribution, and R&D investments. Established manufacturing partnerships ensure volumes support profitability.

What Risks and Opportunities Exist?

Risks:

• Pending patent expiration (2029) invites generic competition.
• Competitive pressure from emerging therapies, potentially including implantable devices.
• Market saturation if hyperkalemia management shifts toward newer modalities.

Opportunities:

• Expansion into inpatient and emergency settings.
• Line extensions targeting related electrolyte disorders.
• Strategic partnerships with payers to enhance formulary inclusion.

Key Takeaways

• MICRO-K, as sodium zirconium cyclosilicate, commands a dominant market share among potassium binders.
• The hyperkalemia market is growing, driven by demographic and clinical factors.
• Financial projections indicate sustained revenue growth through 2028, with margins stabilizing around 22%.
• Patent expiry in 2029 presents a significant competitive threat; until then, exclusivity supports revenue.
• The competitive landscape includes Veltassa, with both drugs priced similarly, emphasizing the importance of prescriber preference and payer policies.

FAQs

1. What differentiates MICRO-K from other potassium binders?
   It has a faster onset of action, improved tolerability, and a convenient dosing schedule, which support clinical adoption.

2. When will generic versions be available?
   Patent protection extends until 2029, after which generic sodium zirconium cyclosilicate products could emerge.

3. How does reimbursement influence MICRO-K's sales?
   Coverage by CMS and private insurers facilitates access, with reimbursement rates comparable to Veltassa.

4. What is the potential for expanding MICRO-K's indications?
   Opportunities exist in inpatient care, acute settings, and treatment of related electrolyte disorders.

5. What impact might new therapies have on MICRO-K’s market share?
   Development of alternative treatments, including implantable devices, could limit growth post-2029 but currently pose limited threats.

---

References

[1] KDIGO Kidney International Supplements, 2022. Global prevalence of CKD.
[2] IQVIA. Prescription Data, 2022.